To tide over the COVID-19 pandemic led crisis, the company in the near-term is deferring its major capex plans, without sacrificing growth, until the business environment stabilises, they said.
The company is focused on generating healthy operating cash flows to further reduce debt levels, the message said.
"We continue to stay focused on our strategy of being closer to the customer and of further strengthening our leadership position in defined businesses," it added.
The company's diversified businesses are segmented in three major verticals namely pharmaceuticals, life science ingredients and drug discovery and development solutions, the report said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.